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Recent studies suggest that chronic kidney disease may induce cardiovascular disease 
through oxidative stress, and that the aging suppressor gene klotho reduces oxidative stress 
in the kidney.  In this study, we examined the changes in klotho gene expression, and the 
renoprotective effects of olmesartan (OLM), angiotensin II receptor blocker (ARB) alone 
or in combination with temocapril (TEM), angiotensin-converting enzyme inhibitor (ACEI) 
in 5/6-nephrectomized (5/6-Nx) spontaneously hypertensive rats. Male 5/6-Nx spontane-
ously hypertensive rats were randomly assigned to 5 groups as follows:  control group; 
5/6-Nx group, 5/6-Nx rats; low OLM group, 5/6-Nx rats administered low-dose OLM (3 
mg/kg/day); high OLM group, 5/6-Nx rats administered high-dose OLM (10 mg/kg/day); 
OLM+TEM group, 5/6-Nx rats administered high-dose OLM and TEM (10 mg/kg/day 
each).  These drugs were administered for 12 weeks.  Systolic blood pressure, glomerular 
sclerosis and transforming growth factor beta 1 mRNA in high OLM and OLM+TEM 
groups were significantly lower than that in the 5/6-Nx group.  Only the OLM+TEM group 
showed improvement of serum creatinine and urinary 8-hydroxy-2'-deoxyguanosine.  Ex-
pression of klotho mRNA, which was downregulated in the 5/6-Nx group, was upregu-
lated in the high OLM and OLM+TEM groups.  OLM dose-dependently prevented klotho 
mRNA downregulation in 5/6-Nx rats, thus confirming a renoprotective effect.  In ad-
dition, combination therapy of OLM and TEM was more effective than OLM alone.  In 
conclusion, the combination of OLM and TEM inhibits the progression of renal damage in 
5/6-Nx rats through the upregulation of klotho gene.
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In chronic kidney disease, in addition to end-stage 
renal disease, mild renal failure can cause cardio-
vascular disease as a result of oxidative stress (Des-
camps-Latscha et al., 2005).  Angiotensin II, through 
the angiotensin II type 1 receptor, increases the 
expression of p47phox, which is a component pro-
tein of NADPH oxidase, and leads to overproduc-
tion of free radicals (Tojo et al., 2002).  Angiotensin 
receptor blocker (ARB) and angiotensin-converting 
enzyme inhibitor (ACEI) inhibit the action of angio-
tensin II, which results in the reduction of oxidative 
stress (Dohi et al., 2003; Fliser et al., 2005).
 The aging suppressor gene klotho, which is 
predominantly expressed in the kidney, prevents 
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insulin and insulin-like growth factor 1 (IGF1) 
signals to reduce oxidative stress (Kurosu et al., 
2005).  It has been reported that angiotensin II, 
through the activation of angiotensin II type 1 re-
ceptor, downregulates the expression of the  klotho 
gene in the kidney, and the introduction of exog-
enous klotho ameliorates renal injury (Mitani et al., 
2002).  In addition, another study showed that the 
renal expression of klotho gene was downregulated 
in patients with chronic renal failure (Koh et al., 
2001).  Furthermore, in chronic kidney disease, 
it has been suggested that the downregulation of 
renal klotho expression is involved in the onset of 
cardiovascular disease.  Taken together, it appears 
that angiotensin II, oxidative stress and the klotho 
gene are closely related to one another, and contrib-
ute to the progression of renal failure and onset of 
cardiovascular disease.
 In this study, we examined the therapeutic ef-
fects of ARB and ACEI on renal damage in 5/6-ne-
phrectomized (5/6-Nx) spontaneously hypertensive 
rats. In addition, we determined the changes in uri-
nary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 
klotho mRNA.
 
 
Materials and Methods
 
 
Animals
 
Male spontaneously hypertensive rats of the Izumo 
strain were purchased from Japan SLC (Shizuoka, 
Japan), and were maintained at a temperature of 24 
± 2°C with a 12-h light-dark cycle.  Animals were 
given standard pellet chow and tap water.  Anes-
thesia was performed by intraperitoneally injecting 
pentobarbital (Dainippon Pharmaceutical, Osaka, 
Japan) at dose of 50 mg/kg.  All experiments were 
carried out in accordance with the Animal Experi-
mentation Guidelines of Tottori University.
 
 
Establishment of model
 
Male 6-week-old spontaneously hypertensive rats 
underwent a 5/6-nephrectomy.  First, the surgical 
excision of approximately 2/3 of the renal cortex 
of the left kidney was performed.  One week later, 
the right kidney was removed.  At 1 week after 
surgery, baseline measurement of body weight, 
blood pressure, urine volume and urinary protein 
was performed.  Blood pressure was measured 
in conscious rats using the tail-cuff method with 
a sphygmomanometer (Softron, Tokyo, Japan). 
Urine was collected from individual rats housed 
in metabolic cages for 24 h.  Administered drugs 
were olmesartan (OLM) as ARB and temocapril 
(TEM) as ACEI.  Rats were divided into 5 experi-
mental groups:  control group, non-nephrectomized 
rats (n = 8); 5/6-Nx group, 5/6-Nx rats (n = 8); low 
OLM group, 5/6-Nx rats administered low-dose 
OLM (3 mg/kg/day); high OLM group, 5/6-Nx 
rats administered high-dose OLM (10 mg/kg/day); 
and OLM+TEM group, 5/6-Nx rats administered 
high-dose OLM and high-dose TEM (10 mg/kg/
day each).  Dosage of each drug was selected based 
on earlier reports so that they would exhibit com-
parable antihypertensive effects (Kanazawa et al., 
2002; Fan et al., 2006).  Drugs were administered 
once a day for 12 weeks beginning 1 week after 
nephrectomy.  Every 4 weeks, we measured body 
weight, blood pressure, urine volume and urinary 
protein in each group.
 After 12 weeks of administration, rats were 
killed under pentobarbital anesthesia. Blood was 
collected from the heart.  Serum samples were fro-
zen and stored at –80°C, and serum creatinine was 
measured.  Remnant kidneys were removed and 
fixed in 10% buffered formalin and embedded in 
paraffin for histological analysis.
 
 
RNA extraction and reverse transcription 
PCR analysis
 
Tissue samples were homogenized and total RNA 
was extracted using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany).  RNA concentration was de-
termined by measuring absorbance at 260 nm and 
the RNA quality was verified by electrophoresis 
on an ethidium-bromide-stained 1% agarose gel. 
About 2 μg of total RNA was reverse transcribed 
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in a final volume of 11.5 μL containing 4 μL of 5× 
standard buffer, 2 μL of 0.1 M dTT, 1 μL of Super-
Script II RNase H-reverse transcriptase (Invitrogen, 
Carlsbad, CA), 2 μL of 10 mM dNTPs (Promega, 
Madison, WI), 1 μL of 50 pmol/μL Random Prim-
er (Promega), 0.5 μL of 100 pmol/μL Oligo (dt) 15 
Primer (Promega) and 1 μL of 40 units/μL Ribonu-
clease Inhibitor (Wako Pure Chemical Industries, 
Osaka).  Samples were incubated at 37°C for 60 
min, followed by 95°C for 5 min and cooling to 
4°C for 5 min.
 
 
Real-time PCR
 
For quantitative real-time PCR, we used 10 µL of 
reverse transcribed samples: PCR grade water, 4.1 
μL; Universal ProbeLibrary probe, 1 μL (Roche, 
Tokyo); Forward primer (10 μM), 0.2 μL; Reverse 
primer (10 μM), 0.2 μL; LightCycler TaqMan 
Master, 2 μL (Roche); and cDNA sample, 2.5 μL. 
mRNA levels of transforming growth factor beta 
1 (TGF- 1) and klotho were assessed by real-time 
PCR assays using -actin as a housekeeping gene. 
The forward and reverse primer sequences used for 
this study are shown in Table 1.  The thermal cy-
cler conditions were as follows: hold at 95°C for 10 
min, repeat 45 cycles of 95°C for 30 s and 60°C for 
1 min.
 
 
Histological analysis
 
Three-micrometer sections of formalin-fixed, 
paraffin-embedded kidneys were stained with pe-
riodic acid-Schiff and periodic acid-methenamine 
silver.  To calculate focal glomerular sclerosis, 100 
to 150 glomeruli from each stained specimen were 
examined.  The degree of sclerosis in each glom-
erulus was subjectively graded on a scale of 0 to 4 
Table 1.  Primer sequences
 Forward primer Reverse primer
TGF- 1 5'-CCTgCCCCTaCaTTTgga-3' 5'-TggTTgTagagggCaaggaC-3'
klotho 5'-CaagaagTTCaTaaTggaaagCTTaaa-3' 5'-aTgCggTgTaCCCaaTgaC-3'
-actin 5'-CTggCTCCTagCaCCaTga-3' 5'-TagagCCaCCaaTCCaCaCa-3'
as follows (Fig. 1):  Grade 0, no change; Grade 1, 
sclerotic area less than or equal to 1/4 of the glom-
erulus or the presence of distinct adhesion between 
the capillary tuft and Bowman’s capsule; Grade 2, 
sclerosis of 1/4 to 1/2 of the total glomerular area; 
Grade 3, sclerosis of 1/2 to 3/4 of the total glom-
erular area; Grade 4, sclerosis of more than 3/4 of 
the glomerulus.  The index of glomerular sclerosis 
was calculated using the following formula (Saito 
et al., 1987):  index of glomerular sclerosis = (1  
N1 + 2  N2 + 3  N3 + 4  N4)/(N0 + N1 + N2 + 
N3 + N4), where N is the number of glomeruli at 
each grade of sclerosis.
 
 
Urinary 8-OHdG measurement
 
Urinary 8-OHdG concentrations were measured by 
enzyme-linked immunosorbent assay (ELISA) us-
ing a commercially available competitive 8-OHdG 
ELISA kit (Japan Institute for Control of Aging, 
Shizuoka).  The kit can measure 8-OHdG values 
ranging from 0.5 to 200 ng/mL using a specific 
monoclonal antibody, N45.1.
 
Statistical analysis
 
Statistical significance of intergroup differences in 
quantitative data was assessed by Student’s t-test 
(Stat View for Windows; SAS Institute, Cary, NC). 
P < 0.05 was considered significant.
 
 
Results
 
Blood pressure
 
Mean systolic blood pressure in the rats dur-
ing the 12-week experimental period is shown 
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in Fig. 2.  Systolic blood pressure after nephre-
ctomy increased progressively throughout the 
experimental period in the 5/6-Nx group.  Drug 
administration induced a significant decrease in 
the treated groups (low OLM, high OLM and 
OLM+TEM groups) when compared with in the 
Fig. 2.  Course of mean systolic blood pressure in the 5 groups.  The systolic blood pressure of rats is significantly de-
creased at 12 weeks of administration in groups of low OLM ( ), high OLM ( ) and OLM+TEM ( ) when compared 
with in the 5/6-Nx group ( ).  , control group.  High OLM, high-dose olmesartan; 5/6-Nx, 5/6-nephrectomized; low 
OLM, low-dose OLM; OLM+TEM, high-dose OLM combined with high-dose temocapril.   
Fig. 1.  Classification of glomerular sclerosis by periodic acid-Schiff stain.  Bar = 100 μm.
0  No change 
1 Sclerosis less than or equal to  
1/4 of the glomerulus or  
the presence of distinct adhesion 
between the capillary tuft and 
Bowman’s capsule
2 Sclerosis of 1/4–1/2 of  
the total glomerular area
3 Sclerosis of 1/2– 3/4 of  
the total glomerular area
4 Sclerosis of more than 3/4  
of the glomerulus
5/6-Nx group.  At the end of the 12-week admin-
istration period, the level was significantly lower 
in the treated groups than in the 5/6-Nx group: 
228 ± 22 for the 5/6-Nx group, 191 ± 15 for the 
low OLM group, 178 ± 27 for the high OLM 
group, 153 ± 16 mmHg for the OLM+TEM group. 
The OLM+TEM group showed significantly lower 
levels than the low OLM group (P < 0.001).
 
 
Proteinuria
 
Figure 3 shows total urinary protein excretion 
in each group during the 12 weeks. The control 
group showed no change, while the 5/6-Nx group 
exhibited progressive increase throughout the ex-
perimental period. During the period, urinary pro-
tein levels were lower in the treated groups than 
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Fig. 3.  Effects of treatments on urinary protein in the 5 groups.  High OLM, high-dose olmesartan; 5/6-Nx, 5/6-ne-
phrectomized; low OLM, low-dose OLM; OLM+TEM, high-dose OLM combined with high-dose temocapril.   
Fig. 4.  Serum creatinine concentrations in the 5 groups at 
12 weeks.  Values are expressed as mean ± SD. *P < 0.05. 
High OLM, high-dose olmesartan; 5/6-Nx, 5/6-nephrecto-
mized; low OLM, low-dose OLM; OLM+TEM, high-dose 
OLM combined with high-dose temocapril.   
in the 5/6-Nx group: especially in the OLM+TEM 
group, the level was significantly lower at 4, 8 and 
12 weeks after the operation. 
 
 
Serum creatinine
 
Figure 4 shows serum creatinine in the 5 groups 
of rats at 12 weeks.  The serum creatinine level 
was significantly higher in the 5/6-Nx group 
than in the control group (P < 0.01).  The treated 
groups (low OLM, high OLM and OLM+TEM 
groups) showed lower levels than the 5/6-Nx 
group; especially, the difference between the 
OLM+TEM and 5/6-Nx groups was significant (P 
< 0.05). 
 
 
Histological findings in the kidney
 
In the control group, only a few sclerotic changes 
of glomeruli and interstitial fibrosis were ob-
served.  The values of the index of glomerular 
sclerosis in the treated groups were significantly 
lower than in the 5/6-Nx group:  P < 0.05 between 
the low OLM and 5/6-Nx groups; P < 0.05 be-
tween the high OLM and 5/6-Nx groups; P < 0.01 
between the OLM+TEM and 5/6-Nx groups.  In 
comparison among the treated groups, the index 
was significantly lower in the OLM+TEM group 
than in the low OLM group (P < 0.05) (Fig. 5).
Fig. 5.  Index of glomerular sclerosis in the 5 groups at 12 
weeks.  Values are expressed as mean ± SD.  *P < 0.05, 
**P < 0.01.  High OLM, high-dose olmesartan; 5/6-
Nx, 5/6-nephrectomized; low OLM, low-dose OLM; 
OLM+TEM, high-dose OLM combined with high-dose 
temocapril.   
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Fig. 7.  Levels of mRNA for transforming growth fac-
tor- 1 (TGF- 1) and klotho gene in renal tissue.
(a) Expression of TGF- 1 mRNA. 
(b) Expression of klotho mRNA. 
Values are expressed as mean ± SEM. *P < 0.05, **P < 
0.01.  High OLM, high-dose olmesartan; 5/6-Nx, 5/6-ne-
phrectomized; low OLM, low-dose OLM; OLM+TEM, 
high-dose OLM combined with high-dose temocapril.   
Fig. 6.  Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG)/
urinary creatinine ratio in the 5 groups at 12 weeks.  Val-
ues are expressed as mean ± SD. *P < 0.05.  High OLM, 
high-dose olmesartan; 5/6-Nx, 5/6-nephrectomized; low 
OLM, low-dose OLM; OLM+TEM, high-dose OLM 
combined with high-dose temocapril.
 
 
Urinary 8-OHdG/urinary creatinine ratio  
 
Levels of urinary 8-OHdG/creatinine in the 5/6-
Nx group at 12 weeks were slightly higher than 
in the control group:  the difference was not sig-
nificant. Levels of urinary 8-OHdG/creatinine in 
the treated groups were lower than in the 5/6-Nx 
group: the difference between the OLM+TEM 
and 5/6-Nx groups was significant (P < 0.05) (Fig. 
6).
 
mRNA quantification of TGF- 1 and klotho
 
The TGF- 1 mRNA level in the 5/6-Nx group was 
markedly increased when compared with in the 
control group (Fig. 7a). This increase was signifi-
cantly alleviated in the high OLM and OLM+TEM 
groups, but not in the low OLM group. The level 
in the OLM+TEM group was significantly lower 
than that in the low OLM group (P < 0.05).
 The klotho mRNA level was significantly 
lower in the 5/6-Nx group than in the control group 
(Fig. 7b). The klotho mRNA levels in the treated 
groups were higher in the 5/6-Nx group:  the high 
OLM and OLM+TEM groups showed significant 
difference to the 5/6-Nx group (P < 0.01).  Among 
the treated groups, levels were significantly higher 
in the high OLM and OLM+TEM groups than in 
the low OLM group (P < 0.05).
 
 
Discussion
 
The rennin-angiotensin system plays an important 
role in the development of hypertension and the 
progression of renal failure.  Numerous studies 
have shown that ARB or ACEI is able to prevent 
the progression of renal failure (Parving et al., 
2001; Nakao et al., 2003; Schmieder et al., 2007). 
ARB or ACEI alleviates glomerular hypertention 
by reducing the constructive effects of angiotensin 
II on the efferent arterioles, which leads to inhibi-
tion of glomerular sclerosis.  Angiotensin II also 
activates the production of free radicals, promotes 
cell growth, and increases the synthesis of inflam-
matory and profibrotic cytokines (Wolf et al., 
2000; Brewster and Perazella., 2004; Long et al., 
2004).  Furthermore, there is increasing evidence 
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supporting a potential role for aldosterone, which 
is stimulated by angiotensin II, in the pathophysi-
ology of renal injury (Hollenberg, 2004; Remuzzi 
et al., 2008).
 Spontaneously hypertensive rats have been 
used as a model for essential hypertension in hu-
mans, and 5/6-Nx rats have commonly been used 
as an experimental model for chronic renal failure 
in humans.  In the present study, we combined the 
2 rat models, and prepared 5/6-Nx spontaneously 
hypertensive rats.  Systolic blood pressure, urinary 
protein and glomerular sclerosis in 5/6-Nx sponta-
neously hypertensive rats increased progressively 
throughout the experimental period.  After 12 
weeks, each of the ARB-treated groups (low and 
high OLM groups) showed a significant decrease 
in systolic blood pressure and index of glomerular 
sclerosis when compared with the 5/6-Nx group. 
These data indicate that OLM ameliorates renal 
injury in a dose-dependent manner.  Indeed, Fan 
et al. also reported that ultrahigh doses of OLM 
showed greater renoprotective effects than typical 
doses of OLM, and that efficacy was independent 
of blood pressure (Fan et al., 2006).
 In our study, the OLM- and TEM-adminis-
tered rats showed greater renoprotective effects 
than only the high OLM-administered rats did, in-
dicating that combination therapy with ARB and 
ACEI has a beneficial effect on renoprotection as 
compared with ARB alone.  It is known that ACE 
inhibition results in reduced degradation of bra-
dykinin (Gavras, 1992), and that bradykinin may 
cause selective efferent arteriolar dilatation and 
stimulate endothelial NO formation.  Jacobsen et 
al. showed that dual blockade of the rennin-angio-
tensin system offers additional renal protection in 
type 1 diabetic patients with diabetic nephropathy 
(Jacobsen et al., 2003).
 TGF- 1 has been shown to play a predomi-
nant role in mediating angiotensin II-induced 
extracellular matrix production and promotes the 
fibrosis of cardiovascular and renal tissues (Saito 
et al., 2004; Dabek et al., 2006).  In the present 
study, renal TGF- 1 mRNA levels were markedly 
lower in the high OLM group and OLM+TEM 
groups.  This suggests that the reduction in TGF- 1 
is closely correlated with the prevention of pro-
gressive renal damage by inhibition of the rennin-
angiotensin system.
 Defects in klotho gene expression in mice 
have been reported to lead to a syndrome closely 
resembling human aging, including shortened life 
span, infertility, arteriosclerosis, osteoporosis and 
pulmonary emphysema (Kuro-o et al., 1997).  The 
klotho gene is expressed in limited tissues, nota-
bly the distal convoluted tubules in the kidney and 
the choroid plexus in the brain.
 klotho protein functions as a circulating 
hormone that binds to a cell-surface receptor and 
represses the intracellular signals of insulin and 
IGF1.  It appears that the anti-aging effects of 
klotho-induced inhibition of insulin/IGF1 signal-
ing are associated with increased resistance to 
oxidative stress (Kurosu et al., 2005).  It has been 
shown that klotho protein inhibits the phospho-
rylation of FoxO forkhead transcription factors, 
which induce expression of manganese superoxide 
dismutase, thereby facilitating removal of reac-
tive oxygen species and conferring resistance to 
oxidative stress (Yamamoto et al., 2005). Mitani 
et al. have demonstrated in experimental models 
that continuous administration of angiotensin II 
reduces renal klotho gene expression (Mitani et 
al., 2002).
 Downregulation of klotho mRNA in the 
kidney has been reported in animal hyperten-
tion models, such as spontaneously hypertensive 
rats and deoxycorticosterone acetate-salt hyper-
tensive rats (Aizawa et al., 1998).  In the present 
study, expression of klotho mRNA in the 5/6-Nx 
group was markedly downregulated when com-
pared with the control group.  This reduction of 
klotho mRNA was ameliorated in the high OLM 
and OLM+TEM groups, but not in the low OLM 
group.  Losartan completely blocked angiotensin 
II-induced klotho mRNA downregulation, which 
is independent of its blood pressure-lowering ef-
fects (Mitani et al., 2002).  This is the 1st report 
showing that OLM dose-dependently prevents 
klotho mRNA downregulation in 5/6-Nx sponta-
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neously hypertensive rats.
 Urinary 8-OHdG is a biological marker of 
in vivo oxidative DNA damage (Shigenaga et al., 
1989), and the average urinary 8-OHdG excretion 
in the OLM+TEM group was significantly lower 
than in the 5/6-Nx group:  this fact indicates that 
OLM- and TEM-induced klotho overexpression 
reduces oxidative DNA damage.  In addition to 
ACEI (de Cavanagh et al., 2000, 2001), OLM 
(Yao et al., 2004) has been reported to improve 
endothelin-induced hypertension and oxidative 
stress in rats.  Fujimoto et al. also reported that 
OLM inhibits superoxide production and oxida-
tive stress, independent of its blood pressure-
lowering effects (Fujimoto et al., 2008).
 A recent study reported that chronic kidney 
disease is an independent risk factor for cardio-
vascular disease, which involves excessive oxida-
tive stress (Descamps-Latscha et al., 2005).  Fur-
thermore, it has been reported that expression of 
the klotho gene in the kidney is downregulated in 
chronic renal failure in vivo (Aizawa et al., 1998) 
and in vitro (Koh et al., 2001).  Saito et al. demon-
strated that klotho gene transfer in an experimen-
tal rat model of atherosclerotic disease improved 
endothelial dysfunction (Saito et al., 2000), and 
that klotho protein protects the cardiovascular sys-
tem through endothelium-derived NO production 
by humoral pathways (Saito et al., 1998).  These 
data suggest that the downregulation of renal 
klotho expression in patients with chronic kidney 
disease is involved in the onset of cardiovascular 
disease. ARB reduced the incidence of cardiovas-
cular disease (Yusuf et al., 2000; de Zeeuw et al., 
2004), which raises the relationship between ARB 
and inhibition of klotho gene downregulation.  In 
the present study, the combination of OLM and 
TEM significantly decreased urinary 8-OHdG, 
and showed renoprotective effects.  These data 
suggest that the combination therapy is more ef-
fective for cardiovascular protection.
 In conclusion, the present study demon-
strated that OLM ameliorates klotho gene down-
regulation in 5/6-Nx rats in a dose-dependent 
manner, and this has a renoprotective effect. In 
addition, combination therapy of OLM and TEM 
was more effective than OLM alone. This sug-
gests that klotho gene upregulation by the rennin-
angiotensin system inhibitor leads to a reduction 
in cardiovascular disease.
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